Cleopatra Hospitals GroupE Valuation

Is CLHO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CLHO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CLHO (EGP8.06) is trading below our estimate of fair value (EGP8.42)

Significantly Below Fair Value: CLHO is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CLHO?

Key metric: As CLHO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CLHO. This is calculated by dividing CLHO's market cap by their current earnings.
What is CLHO's PE Ratio?
PE Ratio	25.7x
Earnings	ج.م453.53m
Market Cap	ج.م11.65b

CLHO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3x
Enterprise Value/EBITDA	12.6x
PEG Ratio	0.8x

Price to Earnings Ratio vs Peers

How does CLHO's PE Ratio compare to its peers?

The above table shows the PE ratio for CLHO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	16.2x
NINH Nozha International Hospital	16x	n/a	ج.م1.8b
ISPH Ibnsina Pharma	15.2x	43.2%	ج.م5.5b
2219 Chaoju Eye Care Holdings	8.5x	14.1%	HK$2.0b
WPH Wattanapat Hospital Trang	25.1x	n/a	฿6.4b
CLHO Cleopatra Hospitals GroupE	25.7x	30.9%	ج.م11.7b

Price-To-Earnings vs Peers: CLHO is expensive based on its Price-To-Earnings Ratio (25.7x) compared to the peer average (16.2x).

Price to Earnings Ratio vs Industry

How does CLHO's PE Ratio compare vs other companies in the Global Healthcare Industry?

11 Companies	Price / Earnings	Estimated Growth	Market Cap

11 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: CLHO is expensive based on its Price-To-Earnings Ratio (25.7x) compared to the Global Healthcare industry average (20.6x).

Price to Earnings Ratio vs Fair Ratio

What is CLHO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CLHO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	25.7x
Fair PE Ratio	19.2x

Price-To-Earnings vs Fair Ratio: CLHO is expensive based on its Price-To-Earnings Ratio (25.7x) compared to the estimated Fair Price-To-Earnings Ratio (19.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CLHO forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	ج.م8.06	ج.م9.50 +17.8%	20.3%	ج.م12.00	ج.م6.89	n/a	5
Nov ’25	ج.م8.25	ج.م9.50 +15.1%	20.3%	ج.م12.00	ج.م6.89	n/a	5
Oct ’25	ج.م7.58	ج.م8.87 +17.1%	18.5%	ج.م11.40	ج.م6.89	n/a	4
Sep ’25	ج.م6.59	ج.م8.83 +34.0%	21.5%	ج.م11.40	ج.م6.89	n/a	3
Aug ’25	ج.م7.07	ج.م8.56 +21.0%	20.5%	ج.م11.40	ج.م6.62	n/a	4
Jul ’25	ج.م7.39	ج.م7.61 +2.9%	9.2%	ج.م8.20	ج.م6.62	n/a	3
Jun ’25	ج.م6.46	ج.م7.54 +16.7%	8.6%	ج.م8.00	ج.م6.62	n/a	3
May ’25	ج.م6.12	ج.م7.54 +23.2%	8.6%	ج.م8.00	ج.م6.62	n/a	3
Apr ’25	ج.م6.96	ج.م7.14 +2.6%	8.6%	ج.م8.00	ج.م6.62	n/a	3
Mar ’25	ج.م6.03	ج.م7.14 +18.4%	8.6%	ج.م8.00	ج.م6.62	n/a	3
Feb ’25	ج.م4.99	ج.م6.98 +39.9%	8.6%	ج.م8.00	ج.م6.50	n/a	4
Jan ’25	ج.م4.72	ج.م6.06 +28.4%	11.7%	ج.م6.62	ج.م5.06	n/a	3
Dec ’24	ج.م5.10	ج.م6.06 +18.8%	11.7%	ج.م6.62	ج.م5.06	n/a	3
Nov ’24	ج.م4.23	ج.م6.06 +43.3%	11.7%	ج.م6.62	ج.م5.06	ج.م8.25	3
Oct ’24	ج.م3.87	ج.م6.06 +56.6%	11.7%	ج.م6.62	ج.م5.06	ج.م7.58	3
Sep ’24	ج.م3.84	ج.م6.17 +60.8%	13.1%	ج.م6.96	ج.م5.06	ج.م6.59	3
Aug ’24	ج.م3.98	ج.م6.36 +59.7%	12.1%	ج.م6.96	ج.م5.06	ج.م7.07	4
Jul ’24	ج.م4.45	ج.م6.38 +43.3%	11.5%	ج.م6.96	ج.م5.15	ج.م7.39	4
Jun ’24	ج.م4.58	ج.م6.38 +39.3%	10.2%	ج.م6.96	ج.م5.15	ج.م6.46	5
May ’24	ج.م4.50	ج.م6.38 +41.8%	10.2%	ج.م6.96	ج.م5.15	ج.م6.12	5
Apr ’24	ج.م4.41	ج.م6.25 +41.8%	10.7%	ج.م6.96	ج.م5.15	ج.م6.96	4
Mar ’24	ج.م5.30	ج.م6.22 +17.3%	11.8%	ج.م6.96	ج.م5.00	ج.م6.03	4
Feb ’24	ج.م5.62	ج.م6.22 +10.6%	11.8%	ج.م6.96	ج.م5.00	ج.م4.99	4
Jan ’24	ج.م5.32	ج.م6.22 +16.8%	11.8%	ج.م6.96	ج.م5.00	ج.م4.72	4
Dec ’23	ج.م4.40	ج.م6.15 +39.8%	11.6%	ج.م6.96	ج.م5.00	ج.م5.10	4
Nov ’23	ج.م4.19	ج.م6.07 +44.9%	13.3%	ج.م6.96	ج.م5.00	ج.م4.23	3

Analyst Forecast: Target price is less than 20% higher than the current share price.